A Phase 1 interventional study of Arm 1: IL13Ra2-specific CAR Tcm cells and Arm 2: IL13Ra2-specific CAR Tcm cells in Recurrent Glioblastoma, Recurrent Malignant Glioma and Recurrent WHO Grade II Glioma, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Glioblastoma by City of Hope Medical Center — 6 open to participants now, 12 under way, none of them phase 3. Glioblastoma · City of Hope Medical Center.
Among the 23 studies in Glioblastoma by City of Hope Medical Center, this one has the largest enrollment of the 22 interventional ones that give a count, is the only one that started in 2015, is one of 20 in phase 1, reaches primary completion later than 0 of the 11 other live ones, and was the 12th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →6 of the 23 studies in Glioblastoma by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
City of Hope Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is above the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 19 across the 22 interventional studies, 160 across the 1 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.
4 of the studies in Glioblastoma by City of Hope Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03389230City of Hope Medical CenterMemory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma | 2026-12-29 |
| NCT07664579City of Hope Medical CenterInvestigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer | 2027-01-04 |
| NCT04661384City of Hope Medical CenterBrain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | 2027-01-12 |
| NCT04214392City of Hope Medical CenterChimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma | 2027-05-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 23 studies in Glioblastoma by City of Hope Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory). A T cell is a type of immune cell that can recognize and kill abnormal cells in the body. T cells are taken from the patient's blood and a modified gene is placed into them in the laboratory and this may help them recognize and kill glioma cells. Genetically modified T-cells may also help the body build an immune response against the tumor cells.
PRIMARY OBJECTIVES:
I. Assess the feasibility and safety of cellular immunotherapy utilizing ex vivo expanded autologous memory-enriched T cells (Arms 1, 2, 3, or 4 = Tcm or Arm 5 = Tn/mem) that are genetically modified using a self-inactivating (SIN) lentiviral vector to express an interleukin 13 receptor alpha 2 (IL13Ra2)-specific, hinge-optimized, 41BB-costimulatory chimeric antigen receptor (CAR), as well as a truncated CD19 (CD19t) for participants with recurrent/refractory malignant glioma in one of the following ways: (1) directly into the tumor (intratumoral), (2) into the tumor cavity (intracavitary), (3) into the lateral ventricles (intraventricular), or (4) into both the tumor/tumor cavity (intratumoral) and into the lateral ventricles (intraventricular) (dual delivery).
II. Determine maximum tolerated dose schedule (MTD)/maximum feasible dose schedule (MFD) and a recommended phase II dosing plan (RP2D) for each arm based on dose limiting toxicities (DLTs) and the full toxicity profile.
SECONDARY OBJECTIVES:
I. In research participants who receive the full schedule of three CAR+ T cell doses:
II. Describe cytokine levels (tumor cavity fluid, CSF, peripheral blood) over the study period.
III. Describe CAR T cell and endogenous immune populations (CSF, tumor cavity fluid, peripheral blood) over the study period; and IV. Identify tumor and tumor micro-environment markers associated with response to CAR T cells.
EXPLORATORY OBJECTIVES:
I. Assess the timing and extent of brain inflammation following CAR T cell administration; II. Evaluate CAR T cell product characteristics; and
III. For research participants who undergo a second resection or autopsy:
OUTLINE: This is a dose-escalation study. Research subjects will receive an initial low dose (cycle 1) followed by 2 additional infusions at a higher cell dose (cycles 2 and 3) of autologous IL13Ra2-CAR/CD19t+ Tcm or Tn/mem, potentially followed by additional cycles at up to the highest tolerated cell dose (cycles 4+). CAR T cells will be administered in one of four ways:
ARM 1: (Intratumoral delivery a/f biopsy): Patients receive IL13Ra2-CAR/CD19t+ Tcm directly into the tumor via intratumoral (ICTb) catheter. Patients who progress on intratumoral administration may move to intraventricular catheter for the optional infusions.
ARM 2: (Intratumoral delivery a/f biopsy/Intracavitary a/f resection): Patients receive IL13Ra2-CAR/CD19t+ Tcm directly into the tumor via intratumoral (ICTb) catheter, or into the tumor resection cavity via intracavitary (ICTr) catheter. Patients who progress on intratumoral/intracavitary administration may move to intraventricular catheter for the optional infusions.
ARM 3: (Intraventricular delivery): Patients receive IL13Ra2-CAR/CD19t+ Tcm via intraventricular (ICV) catheter.
ARM 4: (Dual delivery): Patients receive IL13Ra2-CAR/CD19t+ Tcm via ICTb/r catheter and ICV catheter. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
ARM 5: (Dual delivery): Patients receive IL13Ra2-CAR/CD19t+ Tn/mem via ICTb/r catheter and ICV catheter. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
CAR T cells will be administered at one of three dose schedules:
After completion of the study treatment, patients are followed up at 4 weeks, 3, 6, 8, 10, and 12 months, and then yearly for 15 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Wash-out requirements (standard or ):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1 (Tcm-derived CAR T cells, Intratumoral a/f biopsy \[ICTb\]
Biological: Arm 1: IL13Ra2-specific CAR Tcm cells · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Magnetic Resonance Spectroscopic Imaging · Other: Quality-of-Life Assessment
Arm 2 (Tcm-derived CAR T cells, Intratumoral a/f biopsy \[ICTb\] or Intracavitary a/f resection \[ICTr\])
Biological: Arm 2: IL13Ra2-specific CAR Tcm cells · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Magnetic Resonance Spectroscopic Imaging · Other: Quality-of-Life Assessment
Arm 3 (Tcm-derived CAR T cells, Intraventricular \[ICV\])
Biological: Arm 3: IL13Ra2-specific CAR Tcm cells · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Magnetic Resonance Spectroscopic Imaging · Other: Quality-of-Life Assessment
Arm 4 (Tcm-derived CAR T cells, Dual delivery: both ICTb/r AND ICV)
Biological: Arm 4: IL13Ra2-specific CAR Tcm cells · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Magnetic Resonance Spectroscopic Imaging · Other: Quality-of-Life Assessment
Arm 5 (Tn/mem-derived CAR T cells, Dual delivery: both ICTb/r AND ICV)
Biological: Arm 5: IL13Ra2-specific CAR Tn/mem cells · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Magnetic Resonance Spectroscopic Imaging · Other: Quality-of-Life Assessment
Given via intratumoral catheter
Also known as: Autologous IL13(EQ)BBzeta/CD19t+ Tcm-enriched T Cells, IL13Ra2-CAR/CD19t+ Tcm
Given via intratumoral/intracavitary catheter
Also known as: Autologous IL13(EQ)BBzeta/CD19t+ Tcm-enriched T Cells, IL13Ra2-CAR/CD19t+ Tcm
Given via intraventricular catheter
Also known as: Autologous IL13(EQ)BBzeta/CD19t+ Tcm-enriched T Cells, IL13Ra2-CAR/CD19t+ Tcm
Given via intratumoral or intracavitary, and via intraventricular catheter
Also known as: Autologous IL13(EQ)BBzeta/CD19t+ Tcm-enriched T Cells, IL13Ra2-CAR/CD19t+ Tcm
Given via intratumoral or intracavitary, and via intraventricular catheter
Also known as: Autologous IL13(EQ)BBzeta/CD19t+ Tn/mem-enriched T Cells, IL13Ra2-CAR/CD19t+ Tn/mem
Correlative studies
Correlative studies
Also known as: Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, MRI Imaging, NMRI, Nuclear Magnetic Resonance Imaging
Correlative studies
Also known as: 1H- Nuclear Magnetic Resonance Spectroscopic Imaging, 1H-nuclear magnetic resonance spectroscopic imaging, Magnetic Resonance Spectroscopy, MRS, MRS Imaging, MRSI, Proton Magnetic Resonance Spectroscopic Imaging
Ancillary studies
Number of Participants With Grade 3 or Higher Toxicity Related to CAR T Cells
Grade 3 or higher toxicity profile for adverse events probably or definitely related to CAR T cells as assessed by the NCI CTCAE version 4.0.
Time frame: An average of 11 months
Number of Participants Experiencing a Dose Limiting Toxicity (DLT)
Toxicities will be graded using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. A DLT is defined as events attributable to T-cell infusion (probable or definite) with a few expected events that resolve within a specified time and occurring from the time of initial CAR T cell infusion through 1 week following the last infusion cycle (not including optional cycles) unless otherwise specified in this definition: 1. Two grade 3 toxicities at the same dose with the exception of those grade 3 toxicities listed below. 2. Any grade 3 Cytokine release syndrome (CRS) toxicity lasting more than 72 hours without intervention 3. Any grade 3 or higher allergic reaction 4. Any grade 3 or higher autoimmune reaction 5. Any grade 4 toxicity
Time frame: Up to 1 week following the last course, up to a total of 4 weeks (not including optional courses 4-6)
Number of Participants With Active Response Determined by Response Assessment in Neuro-Oncology (RANO) Criteria
Counts of active response and progression determined by RANO. Participants achieving stable disease (SD), partial remission (PR), or complete remission (CR) are counted as active. RANO: Complete Response (CR): Disappearance of all enhancing disease sustained for 4 weeks, stable or improved FLAIR/T2 lesions, no new lesions, off corticosteroids and neurologically stable or improved. Partial Response (PR): At least a 50% decrease of all measurable enhancing lesions sustained for 4 weeks, no progression of non-measurable disease, stable or improved FLAIR/T2 lesions, no new lesions, corticosteroids dose stable or reduced and neurologically stable or improved. Stable Disease (SD): Does not qualify for CR, PR or PD, stable FLAIR/T2 lesions, stable or reduced corticosteroids, clinically stable Progressive Disease (PD): At least a 25% increase in enhancing lesions despite stable or increasing steroid dose, increase in FLAIR/T2 lesions, any new lesions, clinical deteriorations.
Time frame: Between 4 and 8 weeks post 1st CAR T infusion
Number of Participants Alive at 6 Months
Participants were assessed for vital status up to 6 months post surgery.
Time frame: From surgery to death from any cause or six months, whichever occurred first
| Milestone | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 4 | 4 | 10 | 3 | 3 | 5 | 4 | 8 | 3 | 8 | 11 |
| Completed | 2 | 3 | 4 | 10 | 3 | 3 | 4 | 3 | 5 | 3 | 7 | 11 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 0 | 1 | 0 |
| Withdrew: Participant did not complete treatment | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 1 | 0 |
| Withdrew: Participant received disallowed treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Grade 3 or higher toxicity profile for adverse events probably or definitely related to CAR T cells as assessed by the NCI CTCAE version 4.0.
| Participants | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Encephalopathy — Yes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Encephalopathy — No | 2 | 4 | 4 | 10 | 3 | 3 | 5 | 3 | 8 | 3 | 8 | 11 |
| Ataxia — Yes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Ataxia — No | 2 | 4 | 4 | 10 | 3 | 3 | 5 | 4 | 8 | 3 | 8 | 10 |
Toxicities will be graded using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. A DLT is defined as events attributable to T-cell infusion (probable or definite) with a few expected events that resolve within a specified time and occurring from the time of initial CAR T cell infusion through 1 week following the last infusion cycle (not including optional cycles) unless otherwise specified in this definition: 1. Two grade 3 toxicities at the same dose with the exception of those grade 3 toxicities listed below. 2. Any grade 3 Cytokine release syndrome (CRS) toxicity lasting more than 72 hours without intervention 3. Any grade 3 or higher allergic reaction 4. Any grade 3 or higher autoimmune reaction 5. Any grade 4 toxicity
| Participants | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing a Dose Limiting Toxicity (DLT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Counts of active response and progression determined by RANO. Participants achieving stable disease (SD), partial remission (PR), or complete remission (CR) are counted as active. RANO: Complete Response (CR): Disappearance of all enhancing disease sustained for 4 weeks, stable or improved FLAIR/T2 lesions, no new lesions, off corticosteroids and neurologically stable or improved. Partial Response (PR): At least a 50% decrease of all measurable enhancing lesions sustained for 4 weeks, no progression of non-measurable disease, stable or improved FLAIR/T2 lesions, no new lesions, corticosteroids dose stable or reduced and neurologically stable or improved. Stable Disease (SD): Does not qualify for CR, PR or PD, stable FLAIR/T2 lesions, stable or reduced corticosteroids, clinically stable Progressive Disease (PD): At least a 25% increase in enhancing lesions despite stable or increasing steroid dose, increase in FLAIR/T2 lesions, any new lesions, clinical deteriorations.
| Participants | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active | 0 | 2 | 3 | 5 | 1 | 2 | 2 | 1 | 2 | 0 | 3 | 8 |
| Progression | 2 | 1 | 1 | 5 | 2 | 1 | 2 | 2 | 3 | 3 | 4 | 3 |
Participants were assessed for vital status up to 6 months post surgery.
| Participants | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Alive at 6 Months | 1 | 2 | 2 | 6 | 2 | 3 | 3 | 1 | 2 | 2 | 5 | 8 |
Collected over While on study, an average of 11 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 Dose Schedule 1 | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) |
| Arm 2 Dose Schedule 1 | 4/4 (100%) | 1/4 (25%) | 4/4 (100%) |
| Arm 2 Dose Schedule 2 | 4/4 (100%) | 2/4 (50%) | 4/4 (100%) |
| Arm 2 Dose Schedule 3 | 10/10 (100%) | 2/10 (20%) | 10/10 (100%) |
| Arm 3 Dose Schedule 1 | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Arm 3 Dose Schedule 2 | 2/3 (66.7%) | 0/3 (0%) | 3/3 (100%) |
| Arm 3 Dose Schedule 3 | 4/5 (80%) | 3/5 (60%) | 5/5 (100%) |
| Arm 4 Dose Schedule 1 | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) |
| Arm 4 Dose Schedule 2 | 7/8 (87.5%) | 4/8 (50%) | 8/8 (100%) |
| Arm 5 Dose Schedule 1 | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Arm 5 Dose Schedule 2 | 5/8 (62.5%) | 5/8 (62.5%) | 8/8 (100%) |
| Arm 5 Dose Schedule 3 | 11/11 (100%) | 5/11 (45.5%) | 11/11 (100%) |
| Event | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catheter related infectionInfections and infestations | 0/2 | 0/4 | 2/4 | 0/10 | 0/3 | 0/3 | 0/5 | 0/4 | 0/8 | 1/3 | 0/8 | 1/11 |
| Death NOSGeneral disorders | 0/2 | 0/4 | 0/4 | 1/10 | 0/3 | 0/3 | 1/5 | 0/4 | 1/8 | 0/3 | 3/8 | 0/11 |
| FeverGeneral disorders | 0/2 | 0/4 | 0/4 | 0/10 | 0/3 | 0/3 | 0/5 | 0/4 | 0/8 | 1/3 | 0/8 | 0/11 |
| Lung infectionInfections and infestations | 0/2 | 0/4 | 0/4 | 0/10 | 1/3 | 0/3 | 0/5 | 0/4 | 0/8 | 0/3 | 0/8 | 0/11 |
| Wound dehiscenceInjury, poisoning and procedural complications | 0/2 | 0/4 | 0/4 | 0/10 | 1/3 | 0/3 | 0/5 | 0/4 | 0/8 | 0/3 | 0/8 | 0/11 |
| HeadacheNervous system disorders | 0/2 | 0/4 | 0/4 | 0/10 | 0/3 | 0/3 | 0/5 | 0/4 | 1/8 | 1/3 | 0/8 | 0/11 |
| HydrocephalusNervous system disorders | 0/2 | 0/4 | 0/4 | 0/10 | 1/3 | 0/3 | 0/5 | 0/4 | 1/8 | 0/3 | 1/8 | 0/11 |
| SeizureNervous system disorders | 0/2 | 0/4 | 0/4 | 0/10 | 1/3 | 0/3 | 0/5 | 0/4 | 0/8 | 0/3 | 1/8 | 0/11 |
| Thromboembolic eventVascular disorders | 0/2 | 0/4 | 0/4 | 2/10 | 1/3 | 0/3 | 0/5 | 0/4 | 0/8 | 0/3 | 1/8 | 1/11 |
| SepsisInfections and infestations | 0/2 | 0/4 | 0/4 | 0/10 | 0/3 | 0/3 | 0/5 | 1/4 | 0/8 | 0/3 | 0/8 | 0/11 |
| Event | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 2/2 | 3/4 | 3/4 | 5/10 | 3/3 | 3/3 | 4/5 | 2/4 | 5/8 | 2/3 | 6/8 | 8/11 |
| Sinus bradycardiaCardiac disorders | 2/2 | 1/4 | 3/4 | 5/10 | 2/3 | 3/3 | 3/5 | 4/4 | 4/8 | 1/3 | 3/8 | 6/11 |
| Sinus tachycardiaCardiac disorders | 1/2 | 1/4 | 3/4 | 7/10 | 2/3 | 2/3 | 3/5 | 2/4 | 5/8 | 3/3 | 4/8 | 8/11 |
| NauseaGastrointestinal disorders | 0/2 | 1/4 | 2/4 | 2/10 | 1/3 | 1/3 | 1/5 | 3/4 | 4/8 | 3/3 | 5/8 | 8/11 |
| VomitingGastrointestinal disorders | 0/2 | 0/4 | 2/4 | 2/10 | 1/3 | 1/3 | 2/5 | 2/4 | 4/8 | 3/3 | 2/8 | 7/11 |
| ChillsGeneral disorders | 0/2 | 1/4 | 2/4 | 7/10 | 0/3 | 3/3 | 3/5 | 2/4 | 3/8 | 2/3 | 4/8 | 8/11 |
| FatigueGeneral disorders | 2/2 | 4/4 | 4/4 | 9/10 | 3/3 | 3/3 | 4/5 | 4/4 | 8/8 | 3/3 | 7/8 | 10/11 |
| FeverGeneral disorders | 1/2 | 1/4 | 2/4 | 5/10 | 2/3 | 3/3 | 3/5 | 1/4 | 2/8 | 2/3 | 4/8 | 5/11 |
| PainGeneral disorders | 2/2 | 0/4 | 0/4 | 2/10 | 3/3 | 2/3 | 0/5 | 1/4 | 2/8 | 2/3 | 3/8 | 1/11 |
| Lymphocyte count decreasedInvestigations | 0/2 | 4/4 | 1/4 | 3/10 | 3/3 | 0/3 | 2/5 | 3/4 | 4/8 | 2/3 | 5/8 | 3/11 |
| Age, Continuous(years) | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 52.5 (40 to 65) | 56 (38 to 67) | 55.5 (41 to 70) | 44 (32 to 71) | 56 (44 to 60) | 49 (42 to 57) | 56 (16 to 69) | 59.5 (54 to 65) | 53 (30 to 65) | 32 (32 to 35) | 49 (34 to 56) | 48 (25 to 65) | 49 (16 to 71) |
| Sex: Female, Male(Participants) | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 3 | 0 | 3 | 1 | 0 | 1 | 2 | 3 | 2 | 4 | 5 | 25 |
| Male | 1 | 1 | 4 | 7 | 2 | 3 | 4 | 2 | 5 | 1 | 4 | 6 | 40 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 3 | 11 |
| Not Hispanic or Latino | 1 | 3 | 4 | 8 | 3 | 3 | 5 | 4 | 7 | 3 | 4 | 6 | 51 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 2 | 4 | 3 | 10 | 3 | 3 | 5 | 3 | 6 | 2 | 6 | 8 | 55 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 4 |
| Region of Enrollment(participants) | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 2 | 4 | 4 | 10 | 3 | 3 | 5 | 4 | 8 | 3 | 8 | 11 | 65 |
| Histology(Participants) | Arm 1 Dose Schedule 1 | Arm 2 Dose Schedule 1 | Arm 2 Dose Schedule 2 | Arm 2 Dose Schedule 3 | Arm 3 Dose Schedule 1 | Arm 3 Dose Schedule 2 | Arm 3 Dose Schedule 3 | Arm 4 Dose Schedule 1 | Arm 4 Dose Schedule 2 | Arm 5 Dose Schedule 1 | Arm 5 Dose Schedule 2 | Arm 5 Dose Schedule 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 4 glioblastoma IDH wildtype | 2 | 3 | 3 | 6 | 3 | 2 | 2 | 4 | 6 | 1 | 5 | 10 | 47 |
| Grade 4 diffuse midline glioma, H3 K27-altered | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| Grade 3 astrocytoma, IDH mutant | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| Grade 3 oligodendroglioma, IDH-mutant and 1p/19q-codeleted | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 3 |
| Grade 3 supratentorial ependymoma, NEC | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Grade 4 diffuse astrocytoma, NOS | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Grade 4 astrocytoma, IDH mutant | 0 | 1 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Feb 2021, 68 months.
Results were first posted in Oct 2024, 3 years 8 months after primary completion.
Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's 68 months is above that.
Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.
Start moved once since we started tracking on Sep 25, 2026: May 2015 → Jun 2015, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes